Do we need a new Fleming époque: The nightmare of drug-resistant tuberculosis

International Journal of Mycobacteriology

Volumn 2, Issue 3, 2013, Pages 123-125

  Sotgiu, Giovanni ^a   Centis, Rosella ^b   D'Ambrosio, Lia ^b   Tadolini, Marina ^b   Castiglia, Paolo ^a   Migliori, Giovanni Battista ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

CHINA; CLINICAL RESEARCH; DRUG COST; DRUG RESISTANT TUBERCULOSIS; EDITORIAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FUNDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; INFECTION CONTROL; LABORATORY TEST; MIXED INFECTION; NONHUMAN; OBSERVATIONAL STUDY; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH; RETROSPECTIVE STUDY; RUSSIAN FEDERATION; SOUTH AFRICA; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 84887213349     PISSN: 22125531     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijmyco.2013.07.001     Document Type: Editorial

References (31)

1. Choudhury R., Panda S., Singh D.V. Emergence and dissemination of antibiotic resistance: a global problem. Indian J. Med. Microbiol. 2012, 30(4):384-390.
2. Hawkey P.M., Jones A.M. The changing epidemiology of resistance. J. Antimicrob. Chemother. 2009, 64(Suppl. 1):i3-i10.
3. Hawkey P.M. The growing burden of antimicrobial resistance. J. Antimicrob. Chemother. 2008, 62(Suppl. 1):i1-i9.
4. Raviglione M.C., Lange C., Migliori G.B. Preventing and managing antimicrobial resistance: imperative for chest physicians. Eur. Respir. J. 2011, 37(5):978-981.
5. Migliori G.B., Langendam M.W., D'Ambrosio L., Centis R., Blasi F., Huitric E., et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur. Respir. J. 2012, 40(4):814-822.
6. Langendam M.W., van der Werf M.J., Huitric E., Manissero D. Prevalence of inappropriate tuberculosis treatment regimens: a systematic review. Eur. Respir. J. 2012, 39(4):1012-1020.
7. Van der Werf M.J., Langendam M.W., Huitric E., Manissero D. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur. Respir. J. 2012, 39(6):1511-1519.
8. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., Scheld M., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009 Jan 1, 48(1):1-12.
9. Toman's Tuberculosis: Case Detection, Treatment and Monitoring 2004, World Health Organization, WHO, Geneva. second ed.
10. Espinal M.A., Kim S.J., Suarez P.G., Kam K.M., Khomenko A.G., Migliori G.B., et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000, 283:2537-2545.
11. Orenstein E.W., Basu S., Shah N.S., Andrews J.R., Friedland G.H., Moll A.P., et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect. Dis. 2009, 9(3):153-161.
12. World Health Organization, Guidelines for the programmatic management of drug-resistant tuberculosis, Emergency, update 2008. WHO/HTM/TB/2008.402.
13. Falzon D., Jaramillo E., Schünemann H.J., Arentz M., Bauer M., Bayona J., Blanc L., et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur. Respir. J. 2011, 38(3):516-528.
14. Skrahina A., Hurevich H., Zalutskaya A., Sahalchyk E., Astrauko A., van Gemert W., et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur. Respir. J. 2012, 39(6):1425-1431.
15. Migliori G.B., Dara M., de Colombani P., Kluge H., Raviglione M.C. Multidrug-resistant tuberculosis in Eastern Europe: still on the increase?. Eur. Respir. J. 2012, 39(6):1290-1291.
16. De Lorenzo S., Alffenaar J.W., Sotgiu G., Centis R., D'Ambrosio L., Tiberi S., et al. Efficacy and safety of meropenem/clavulanate added to linezolid containing regimens in the treatment of M/XDR-TB. Eur. Respir. J. 2013, 41(6):1386-1392.
17. Skripconoka V., Danilovits M., Pehme L., Tomson T., Skenders G., Kummik T., et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur. Respir. J. 2013 Jun, 41(6):1393-1400.
18. Diacon A.H., Dawson R., von Groote-Bidlingmaier F., Symons G., Venter A., Donald P.R., et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012 Sep 15, 380(9846):986-993.
19. Migliori G.B., Sotgiu G. Treatment of tuberculosis: have we turned the corner?. Lancet 2012 Sep 15, 380(9846):955-957.
20. Migliori G.B., Besozzi G., Girardi E., Kliiman K., Lange C., Toungoussova O.S., et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur. Respir. J. 2007, 30:623-626.
21. Migliori G.B., Lange C., Girardi E., Centis R., Besozzi G., Kliiman K., Ortmann J., et al. SMIRA/TBNET Study Group. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results. Clin. Infect. Dis. 2008, 46(6):958-959.
22. Migliori G.B., Lange C., Centis R., Sotgiu G., Mütterlein R., Hoffmann H., et al. TBNET Study Group. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur. Respir. J. 2008, 31(6):1155-1159.
23. Sotgiu G., Ferrara G., Matteelli A., Richardson M.D., Centis R., Ruesch-Gerdes S., et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur. Respir. J. 2009, 33(4):871-881.
24. World Health Organization (2012) Global tuberculosis report 2012. WHO/HTM/TB/2012.6. Geneva: WHO, 2012.
25. Migliori G.B., De Iaco G., Besozzi G., Centis R., Cirillo D.M. First tuberculosis cases in Italy resistant to all tested drugs. Euro. Surveill. 2007, 12(5). E070517.1.
26. Velayati A.A., Masjedi M.R., Farnia P., Tabarsi P., Ghanavi J., Ziazarifi A.H., et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009, 136:420-425.
27. Velayati A.A., Farnia P., Masjedi M.R., Ibrahim T.A., Tabarsi P., Haroun R.Z., et al. Totally drug-resistant tuberculosis strains: evidence of adaptation at the cellular level. Eur. Respir. J. 2009, 34(5):1202-1203.
28. Udwadia Z.F., Amale R.A., Ajbani K.K., Rodrigues C. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 2012, 54:579-581.
29. Migliori G.B., Sotgiu G., Gandhi N.R., Falzon D., Deriemer K., Centis R., et al. The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Drug resistance beyond XDR-TB: results from a large individual patient data meta-analysis. Eur. Respir. J. 2012, (Epub ahead of print).
30. Falzon D., Gandhi N., Migliori G.B., Sotgiu G., Cox H., Holtz T.H., et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur. Respir. J. 2012, (Epub ahead of print).
31. Migliori G.B., Sotgiu G., Lange C., Centis R. Extensively drug-resistant tuberculosis: back to the future. Eur. Respir. J. 2010, 36(3):475-477.